Synthos Bio reads across 20 million+ peer-reviewed scientific papers simultaneously to find novel therapeutic solutions hiding between disciplines no one thought to connect.
Our AI ingests the entirety of published biomedical research, not just abstracts or keywords, but the full mechanistic detail of every discoverable study across every discipline.
Scientific research is published in silos. A cardiology finding and a neurology finding may share a mechanism no human researcher would ever see. Our AI sees all of them, all the time.
We assemble specific drugs, for defined patient populations, grounded in published evidence. These are novel therapeutic concepts that did not previously exist as coherent clinical ideas.
Each solution is filed as intellectual property and licensed to pharmaceutical companies equipped to bring them through clinical development and to market.
Every drug in our pipeline traces back to real, peer-reviewed discoveries. We do not generate hypothetical molecules. We do not hallucinate mechanisms. We find therapeutic solutions that already have evidentiary support, scattered across publications that were never meant to be read together.
Our lead provisional patent was filed April 1, 2026 (USPTO Application No. 64/025,012). The pipeline spans hematology, cardiology, hepatology, pulmonology, neurology, oncology, and hereditary cancer prevention.
"The cures for medicine's most stubborn problems are hiding in plain sight, scattered across disciplines that have never been connected. We read everything. We connect everything. We build the medicines."
Synthos Bio exists to advance medicine 100 years in the span of one.